The nasal packing devices market comprises absorbable and non-absorbable devices used to manage epistaxis (nosebleeds), postoperative nasal care, and nasal surgeries such as septoplasty, sinus surgery, and rhinoplasty. These devices help in supporting nasal structures, reducing bleeding, minimizing adhesions, and promoting mucosal healing.
They are typically made from hydrophilic polyvinyl alcohol (PVA), carboxymethylcellulose, hyaluronic acid, chitosan, and silicone, and are available in various forms including gauze strips, nasal tampons, sponges, and inflatable balloons.
In 2025, the global nasal packing devices market is projected to reach approximately USD 209.2 million, with expectations to grow to around USD 337.5 million by 2035, reflecting a Compound Annual Growth Rate (CAGR) of 4.9% during the forecast period.
Key Market Metrics
| Metric | Value |
|---|---|
| Market Size in 2025 | USD 209.2 Million |
| Projected Market Size in 2035 | USD 337.5 Million |
| CAGR (2025 to 2035) | 4.9% |
Growth in this market is driven by increasing prevalence of chronic sinusitis, trauma cases, ENT surgeries, and innovations in biocompatible, absorbable, and patient-friendly packing materials.
The majority of the nasal packing devices market has been captured by North America owing to the highest rate of ENT procedures, reimbursement and advanced healthcare infrastructure. There is a strong demand for absorbable nasal packing in outpatient sinus surgery in the United States, and the increasing adoption of tele-ENT consultations are boosting awareness of minimally invasive procedures.
Clinical take-up of bioresorbable and chitosan-based devices is another factor supporting market growth, as these technologies minimize patient discomfort and follow-up removals.
Germany, France, the UK, and Italy are the top contributors to Europe's market share, attributed to the increasing prevalence of allergic rhinitis, chronic sinusitis, and expanding ambulatory ENT procedures. The region has a high demand for soft, hypoallergenic and antibiotic coated nasal packs.
Asia-Pacific is expected to have the fastest growth, owing to the rising prevalence of ENT diseases, increasing surgical volumes and improving access to specialized otolaryngology care in China, India, Japan and South Korea. The growing awareness regarding the accessibility of affordable local products, and the government's initiatives for ENT camps and outreach in the countryside are propelling the market further from metropolitan places.
Patient Discomfort, Risk of Adhesion, and Limited Reimbursement
Nasal packing devices market is still ongoing challenges related to patient discomfort, especially due to rigid or non-absorbable nasal packs that result in pain, mucosal injury, or synechiae formation upon removal. Moreover, factors like no standardized regimens for post-operative care and the heterogeneity in ENT surgical techniques further exasperate both product choice and clinician uptake.
Lack of coverage by reimbursement programs, especially for new bioresorbable technologies and in-office practices, is a limitation associated with reforming healthcare systems. Other factors leading to the complication rate include infection risk and user compliance with care after packaging.
Bioabsorbable Materials, Minimally Invasive ENT Procedures, and Outpatient Expansion
Combined with these disadvantages, the industry is positioned to expand by means of improvements to bioabsorbablehemostatic nose packing gadgets available with less patient distress, antimicrobial features, and don't require removal. Novel chitosan-based sponges, hyaluronic acid-releasing tampons, and shape-memory foam are among those improving clinical outcomes after surgery (septoplasty, FESS, turbinate reduction).
The growth of day-care ENT procedures, wider application of nasal endoscopes, and broader use of ambulatory surgical centers (ASCs) provide new platforms for growth. Other trends such as the incidence of sinusitis, nasal trauma, and cosmetic rhinoplasties drive procedural volumes globally.
Between 2020 to 2024,nasal packing was increasing owing to rhinologic surgical recovery, management of epistaxis and absorbable nasal packs being placed within affluent settings. Cost constraints and clinician training deficits limited use of advanced materials in developing countries, where gauze-based or inflatable packings remained the norm.
Then, from 2025 to 2035, the field will continue to shift towards patient-focused, dissolvable, and drug-eluting nasal packings, driven by minimally invasive ENT device expansion, AI-based nose diagnostics, and clinical data for comfort and lower complication.
Market Shifts: A Comparative Analysis 2020 to 2024 vs. 2025 to 2035
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | CE and FDA approvals for polyvinyl alcohol (PVA), gauze, and foam-based packings |
| Technology Innovations | Use of expandable foam, inflatable balloon systems, and surgical gauze |
| Market Adoption | Common in ENT hospitals, emergency care, and trauma management |
| Sustainability Trends | Early initiatives around latex-free, hypoallergenic packaging |
| Market Competition | Led by Medtronic, Stryker, Smith & Nephew, Summit Medical, Lohmann & Rauscher, Boston Medical Products |
| Consumer Trends | Preference for faster healing, less pain, and fewer follow-up visits |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Broader approval of bioresorbable, antibiotic-coated, and hemostatic -enhanced materials with performance-based classification |
| Technology Innovations | Growth in chitosan, carboxymethylcellulose, gelatin, and hydrogel-based resorbable packings |
| Market Adoption | Expansion into office-based ENT practices, ambulatory care, and rhinoplasty recovery kits |
| Sustainability Trends | Shift toward biodegradable, plant-based polymers and zero-waste surgical kits |
| Market Competition | Entry of bioresorbable tech startups, minimally invasive ENT device firms, and hybrid drug-device manufacturers |
| Consumer Trends | Demand for comfort-enhanced, dissolvable, antimicrobial nasal packings with digital post-op care support |
The United States nasal packing devices market is entering in a very rapid growth phase by predominately supported with the growing prevalence of epistaxis (nosebleeds) among the population, rise in ENT procedures and high rate of chronic sinusitis and nasal surgeries.
Growing population base with the need for ENT specialists and better access to these specialists results in an increase in demand for absorbable and non-absorbable nasal packing solutions. Technology is making product lines richer with drug-eluting, biodegradable, hemostatic. In addition, rising patient volume of outpatient ENT procedures is propelling adoption of easy-to-use nasal packing kits in ambulatory facilities.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 5.2% |
The UK nasal packing devices market has moderate growth owing to NHS uptake of minimally invasive ENT procedures and growing application of nasal packing in trauma care and elective nasal surgeries.
Increasing awareness of post- operative care and rising usage of absorbable nasal packs in sinus and septoplasty therapies propel the market growth. Also, clinician preference for devices that are low-irritation and antimicrobial-coated is becoming a factor in hospital purchasing decisions.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 4.7% |
Germany, France and Netherlands have developed otolaryngology practice in these countries and a rising trend towards growth in the EU Nasal Packing Devices market. Additionally, major application segments are about ENT procedures, supported by chronic rhinitis, deviated septum, and nasal polyps.
Several packing manufacturers are ensuring compliance with stringent regulations under MDR to promote adoption of biocompatible and CE-marked packing materials. Instead of gauze, clinics and hospitals are choosing packing devices that are comfort-based, anti-adhesion and bioabsorbable to reduce the need for follow-ups.
| Region | CAGR (2025 to 2035) |
|---|---|
| EU | 4.6% |
The Japan nasal packing devices market is gaining steady momentum due to increasing adoption of ENT surgeries by its elderly people along with rising awareness regarding minimally invasive treatment procedures.
Japanese healthcare units prefer small, high absorption, and painless removal penetrable nasal packs. Domestic companies are seeking antimicrobial or anti-inflammatory coated versions that promote post-surgical recovery and patient comfort.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 4.9% |
In South Korea, the nasal packing devices market is booming, owing to the amalgamation of aesthetic nasal surgeries (like rhinoplasty), a prevalence of allergic rhinitis, and fast-paced healthcare modernization.
Increasing use of advanced, sponge based and biodegradable nasal packing systems in ENT clinics and tertiary care hospitals. Local manufacturing of affordable and innovative nasal packs is also strengthening the domestic supply chain of the country.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 5.0% |
| Source Type | Market Share (2025) |
|---|---|
| Gel | 52.4% |
Gel-based nasal packing products are expected to lead the market for nasal packing devices across the globe, obtaining 52.4% of the share in overall product by 2035. For the popularity of gel products is that they enable faster haemostasis, improved mucosal protection, and increased patient comfort. Unlike traditional gauze or rigid dressing techniques, gel-based packing conforms to the anatomical landmarks in the nasal cavity, resulting in more even pressure distribution and minimal trauma to the mucosa.
For instance, the gel-based nasal packing have the advantages such as biocompatibility and non-adherency. Conventional dressing does not get removed easily by ENT specialists following surgeries such as septoplasty, turbinectomy and functional endoscopic sinus surgery (FESS).
In contrast, gel packings resorb spontaneously or are gently washed out with minimal discomfort and less secondary intervention and improved outcomes in patients. These traits especially attribute to their focused and increasing popularity among the private ENT clinics and outpatient surgical centers.
Clinical evidence supports the use of gel preparations for preventing postoperative bleeding, synechiae and infection in surgical practice. Products that contain chitosan, hyaluronic acid or carboxymethylcellulose as gel bases have the ability not only to ensure haemostasis, but also to accelerate wound healing.
According to surgeons, these preparations reduce crusting and correlate with more rapid epithelialization, an early consideration in healing. The rationale for these two simultaneous actions of stopping bleeding from one side of the spectrum while promoting mucosal regeneration from the other has been a prominent contributor to the widespread acceptance of gel-based nasal packing not just in elective surgery but also in emergency trauma care.
Gel-based products account for a large part of the market revenue as they are easier to apply than RAW (powder) products. The gel, which can be applied directly into the nasal cavity quickly and precisely, comes in ready-for-use, pre-filled syringes or single-dose ampoules.
Such pre-formulated designs mitigate procedural time and reduce the chances of contamination. These savings are valued by hospitals and ambulatory surgical facilities, especially in high-throughput settings where operating room turnover and infection prevention are top-of-mind considerations.
The growing demand for minimally invasive sinus surgery also helped create a place for gel-based nasal packing. With more widespread use of image-guided endoscopic procedures and balloon sinuplasty, we as surgeons become more tolerant of soft, pliable packings that do not impede postoperative visualization or diagnostics imaging.
Gel-based materials are used to reduce nasal stuffiness and pulmonary obstruction, and in most cases, patients have less nasal obstruction and breathing impairment, which results in higher postoperative satisfaction and lower complication rates.
Conversely, various configurations for other products such as foams, sprays, and dressings still play a role but are generally not very versatile and acceptable by patients. Injectable foams provide expansion-based haemostasis but are difficult to limit and risk excessive pressure on friable mucosa.
For moderate-to-severe bleeding, however, sprays fall short as they are effective in surface haemostasis but lack the volumetric fill. Dressings, especially if they are non-resorbable, are still associated with patient discomfort, pain during removal, and a higher risk of secondary trauma.
Overall, translate from gel for nasal packing are selecting up as the system of choice for surgical and nonsurgical implementations since of the exceptional mixture of ease-of-use, biocompatibility and therapeutic action. With increasing pressure for clinical efficacy to be matched with comfort for the patient, the gel segment will retain its stronghold over the next decade.
| Form Type | Market Share (2025) |
|---|---|
| Bio- resorbable | 47.6% |
Bio-resorbable nasal pack devices are expected to lead the global ENT practice and take 47.6% of the overall market. The fact that they convey therapeutic benefits without requiring physical extraction has transformed postoperative care standards, particularly in instances where sensitive or inflamed nasal tissue is in play.
With patient comfort and recuperation, not to mention protection against infection taking priority in surgical planning, new bio-resorbablepackings offer invaluable clinical and psychological benefits. Unlike traditional packings which need to be removed manually days after surgery, bio-resorbable devices undergo spontaneous degradation in the nasal cavity, usually over a period of 5 to 14 days.
This negates the need for removal in separate follow-up visits, which proves not only to reduce discomfort and anxiety in patients, but also to free up clinical resources. In a high volume health system, every minute saved from self-dissolving materials is a giant vote for your operational effectiveness and clinical throughput.
The science of bio-resorbable packaging has matured to deliver a wide array of therapeutic benefits beyond just structural support. That includes many formulations with hydrogels, oxidized cellulose or bioactive polymers that release therapeutic agents as they resorb.
Agents, such as antibiotics; antifungals; anti-inflammatories; and/or growth factors that help to prevent infection, the formation of a scar, and induce mucosal repair are placed. This multi-benefit capability is complementary to the overall healthcare movement toward value-based care, where a single intervention will yield more than one benefit.
Bio-resorbable materials are particularly attractive in pediatric and geriatric patients, who have decreased tolerance to foreign bodies and increased damage to mucosa from packing extraction. Surgeons who work on these populations say that bio-resorbable materials reduce septal perforations, adhesions and delayed healing. The psychological benefit for patients with no procedure to later remove also improves postoperative compliance and patient satisfaction percentages.
Regulatory enablement of bio-resorbable nasal packings has been rapid, paralleled by clinical guidelines evolution. The current preference of ENT societies and surgical boards is for patients with a high risk of bleeding, complex anatomical variations and for those on anticoagulants, use bio-resorbable materials.
These guidelines have shaped clinicians' purchasing decisions as well as the insurers' decision to reimburse resorbable usage in approved indications. Thus, the bio-resorbablepackings becoming all the more common on a case-to-case basis in the field of ENT surgery.
Environmental and logistical factors have also played a role in the shift toward resorbable materials. With the world hungering for medical sustainability, less waste and follow-up procedures equals smaller environmental footprint. Moreover, the use of single-use resorbable devices would be in line with infection control measures since it reduces the need for additional instruments or manual manipulation, especially within a resource-limited environment.
While non-absorbable packings will always have a place in the emergency room, trauma stabilization, and some complex surgical conditions, their market share is slowly fading in light of bio-resorbable variants coming up.
Conventional non-absorbable devices are typically rigid or semi-rigid, and are manually removed between 24-72 hours, a process that is often described from patient feedback as painful or uncomfortable. Extraction of non-resorbablepackings can lead to hemorrhage, inflammation, or affective distress in patients with anxiety disorders or a history of traumatic events, despite anesthetic cover.
Moreover, the risks associated with non-resorbable devices that remain in the patient, such as foreign body reaction, secondary infection or impaired healing due to mechanical friction, are becoming more recognized by healthcare professionals. Conversely, bio-resorbable materials have been engineered to resorb over the time-course of natural mucosal healing, thereby reducing complications and simplifying care provision.
So, bio-resorbable nasal packing devices have changed the standard of care as they bridge the gap between efficacy in surgery and patient outcomes. As a result, when they break down safely, aid in healing, reduce complications, and prevent painful extractions, they become the future of ENT post-procedure care. The global nasal packing devices market will grow with increasing implementation of evidence-based, less invasive types of care, and dominance of the bio-resorbable category.
The global nasal packing devices market is anticipated to be driven by growing prevalence of nasal surgeries (septoplasty, FESS), epistaxis (nosebleed), and sinusitis. Nasal packing devices are used to control bleeding, stabilize the nasal cavity, prevent adhesions, and improve healing after surgery.
The factors contributing to this rise in market growth include growing ENT procedures, increasing demand for absorbable and biocompatible materials, innovations in hemostatic agent technology, and expanding outpatient ENT clinics.
Market Share Analysis by Key Players
| Company/Organization Name | Estimated Market Share (%) |
|---|---|
| Smith & Nephew plc | 18-22% |
| Medtronic plc | 14-18% |
| Stryker Corporation | 12-16% |
| Olympus Corporation | 10-14% |
| Summit Medical, Inc. ( Innovia Medical) | 8-12% |
| Others | 26-32% |
| Company/Organization Name | Key Offerings/Activities |
|---|---|
| Smith & Nephew plc | In 2024, Smith & Nephew launched PVA-based and hemostatic nasal packing devices under its ENT line, optimized for minimal mucosal trauma and rapid fluid absorption. |
| Medtronic plc | As of 2023, Medtronic expanded its Nellcor ™ Nasal Packing range, focusing on bioresorbable and expandable foam-based packs for post-operative nasal cavity stabilization. |
| Stryker Corporation | In 2024, Stryker introduced Clearpath ™ nasal spacers and dissolvable gel packs, supporting sinus healing and septum stabilization after endoscopic procedures. |
| Olympus Corporation | In 2023, Olympus debuted nasal dressing kits integrated with suction-irrigation systems, enhancing use in ambulatory ENT and rhinoplasty centers . |
| Summit Medical, Inc. | As of 2025, Summit launched its RhinoGuard ™ and Rapid Rhino® nasal packs using carboxymethylcellulose and inflatable balloon-based designs, widely adopted in emergency care and hospitals. |
Key Market Insights
Smith & Nephew plc (18-22%)
Smith & Nephew dominates the nasal packing market with its ENT-specific post-operative packing devices, known for biocompatibility, anti-adhesion performance, and fast absorption, especially in otolaryngology clinics across North America and Europe.
Medtronic plc (14-18%)
Medtronic provides bioresorbable and hemostatic nasal packing solutions, supporting minimally invasive nasal surgeries with strong adoption in hospital systems and surgical centers.
Stryker Corporation (12-16%)
Stryker’s nasal packing products emphasize comfort and post-op compliance, offering dissolvable formats that reduce follow-up removals and patient discomfort, ideal for sinus surgeries.
Olympus Corporation (10-14%)
Olympus enhances the intraoperative utility of nasal packing devices, integrating irrigation and visualization systems, serving both rhinology and endoscopy segments.
Summit Medical, Inc. (8-12%)
Summit’s Rapid Rhino® and balloon-based nasal packs are widely used for anterior and posterior epistaxis, known for quick deployment, minimal insertion trauma, and secure anchoring.
Other Key Players (26-32% Combined)
Several specialized and regional players are expanding the nasal packing market with customized, cost-effective, and material-diverse solutions, including:
The overall market size for nasal packing devices market was USD 209.2 million in 2025.
The nasal packing devices market is expected to reach USD 337.5 million in 2035.
Increasing cases of chronic sinusitis and nasal surgeries, rising preference for minimally invasive ENT procedures, and growing use of absorbable nasal packing materials will drive market growth.
The top 5 countries which drives the development of nasal packing devices market are USA, European Union, Japan, South Korea and UK.
Bio-resorbable expected to grow to command significant share over the assessment period.
Explore Therapeutic Device Insights
Nasal Packing Devices Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
